Brokerages Set Zura Bio Limited (NASDAQ:ZURA) Target Price at $10.75

Shares of Zura Bio Limited (NASDAQ:ZURA) have been assigned a consensus recommendation of “Moderate Buy” from the six research firms that are covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and four have assigned a buy recommendation to the company. The average 1 year price objective among brokers that have issued a report on the stock in the last year is $10.75.

Several research analysts have commented on ZURA shares. Chardan Capital restated a “buy” rating and set a $10.00 price objective on shares of Zura Bio in a report on Friday. Oppenheimer cut their price target on Zura Bio from $17.00 to $16.00 and set an “outperform” rating on the stock in a research note on Friday, August 15th. HC Wainwright lowered their price objective on shares of Zura Bio from $3.00 to $2.00 and set a “neutral” rating for the company in a research note on Tuesday, August 19th. Wall Street Zen cut shares of Zura Bio from a “hold” rating to a “sell” rating in a report on Sunday. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Zura Bio in a research report on Tuesday, October 14th.

Zura Bio Price Performance

Zura Bio stock opened at $3.99 on Friday. The stock has a market cap of $259.43 million, a price-to-earnings ratio of -6.14 and a beta of 0.24. The firm has a 50-day moving average of $3.34 and a two-hundred day moving average of $2.09. Zura Bio has a 1 year low of $0.97 and a 1 year high of $4.68.

Zura Bio (NASDAQ:ZURA) last issued its earnings results on Thursday, November 13th. The company reported ($0.21) EPS for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.02). Research analysts expect that Zura Bio will post -0.65 earnings per share for the current year.

Institutional Trading of Zura Bio

Several hedge funds and other institutional investors have recently bought and sold shares of ZURA. Savant Capital LLC increased its holdings in shares of Zura Bio by 190.4% in the 2nd quarter. Savant Capital LLC now owns 32,409 shares of the company’s stock valued at $34,000 after acquiring an additional 21,249 shares during the period. Scientech Research LLC bought a new stake in Zura Bio during the third quarter valued at about $45,000. AQR Capital Management LLC purchased a new position in Zura Bio in the first quarter valued at about $72,000. Nuveen LLC bought a new position in Zura Bio in the first quarter worth about $76,000. Finally, Forefront Wealth Partners LLC bought a new position in Zura Bio in the third quarter worth about $93,000. Institutional investors own 61.14% of the company’s stock.

Zura Bio Company Profile

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.